Eli Lilly Wins Early Round in Novo Nordisk Ad Fight

What happened

A US judge rejected Novo Nordisk's request to temporarily stop Eli Lilly from advertising Zepbound and Mounjaro. Novo sued in July, claiming Lilly's ads were deceptive by equating larger doses of its drugs to lower levels of Wegovy and Ozempic. The court did not rule on whether the ads were legal.

Confirmed

Global impact / market context

The ruling removes an immediate marketing restriction on Lilly, which means it can keep promoting its weight-loss drugs while the case continues. Both companies compete in a weight-loss industry worth tens of billions of dollars yearly, so advertising affects prescriptions, revenue and investor expectations.

Analyst inference

The judge noted Novo's prescriptions stayed steady during the relevant period, suggesting the challenged ads had limited market impact. That weakens Novo's claim of long-term harm to sales, goodwill or clinical reputation, reducing near-term legal risk for Lilly while the broader dispute continues.

Analyst inference

What to watch

1. Novo Nordisk sued in July, saying Lilly's advertising was deceptive and misleading because it equated larger dosages of its medications to lesser levels of Wegovy and Ozempic. The legal dispute is far from finished. Confirmed
2. Watch whether Novo can establish its false-advertising charges as the case progresses, since the judge only rejected a temporary advertising ban and did not decide whether the commercials were ultimately legal. Proposed
3. Watch prescriptions and advertising spending for Zepbound, Mounjaro, Wegovy and Ozempic, because steady prescription trends during the relevant period were cited as evidence the challenged ads had only limited market impact. Analyst inference

Evidence

• gurufocus.com